BioCentury

1:33 AM GMT, Oct 16, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical News

Lilly's ramucirumab meets OS endpoint in gastric cancer

Eli Lilly and Co. (NYSE:LLY) said ramucirumab met the primary endpoint in the Phase III REGARD

Read the full 168 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.